Caso contributivo
Sindrome da encefalopatia posteriore reversibile.
Neurotossicità da ciclosporina
Posterior reversible encephalopathy syndrome. Cyclosporine neurotoxicity
Maria Valentina Abate1, Anna Proia2, Anna Locasciulli3, Alessandro Ventura1
1IRCCS Materno-Infantile “Burlo Garofolo”, Università di Trieste
2Ematologia e Centro Trapianti Cellule Staminali, 3Dipartimento di Pediatria ed Ematologia Pediatrica, Azienda Ospedaliera San Camillo-Forlanini, Roma
Ottobre 2015
Abstract
Reversible posterior encephalopathy syndrome (PRES) is a clinic-radiologic syndrome characterized by headache, altered mental status, visual and motor symptoms and radiological lesions documented on brain MRI. PRES is characterized by a complete reversibility and is probably the expression of a vasogenic oedema. The paper de-scribes a case of a 16-year-old boy affected by Fanconi’s anaemia who underwent allogenic bone marrow trans-plantation.
Contenuto riservato
Per leggere l'articolo è necessario effettuare il login.
Parole chiave
Bibliografia
Bibliografia
Ni J, Zhou LX, Hao HL, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging 2011;21(3):219-24.
Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008;29(6):1036-42.
Van Diest D, Van Goethem JW, Vercruyssen A, Jadoul C, Cras P. Poaterior encephalopathy syn-drome and Guillain Barre syndrome in a single patient coincidence or causative relation? J Neurol Neurosurg 2007;109(1):58-62.
Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999;246(5):339-46.
Casey SO, Sampaio RC, Michel E, Truwit CL. Posterior reversible encephalopathy syndrome: utility of fl uidattenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000;21(7):1199-206.
Uckan D, Cetin M, Yigitkanli I, et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant 2005;35:71-6.
Striano P, Striano S, Tortora F, et al. Clinical spectrum and critical care management of posterior reversible encephalopathy syndrome (PRES). Med Sci Monit 2005;11(11):CR549-53.
Servillo G, Bifulco F, De Robertis E, et al. Posterior reversible encephalopathy syndrome in in-tensive care medicine. Intensive Care Med 2007;33(2):230-6.
Minn AY, Fisher PG, Barnes PD, Dahl GV. A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation. Pediatr Blood Cancer 2007;48(2):213-7.
Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: is there a difference between pregnant and non-pregnant patients? Eur Neurol 2009;62:142-8.
Natsume J, Sofue A, Yamada A, Kato K. Electroencephalographic (EEG) findings in posterior reversible encephalopathy associated with immunosuppressants. J Child Neurol 2006;21(7):620-3.
Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: long-term follow-up. J Neurol Neurosurg Psychiatry 2010;81(7):773-7.
Gümüş H, Per H, Kumandaş S, Yikilmaz A. Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. Neurol Sci 2010;31(2):125-31.
McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: inci-dence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 2007;189:904-12.
Ulrich K, Tröscher-Weber R, Tomandl BF, Neundörfer B, Reinhardt F. Posterior reversible en-cephalopathy in eclampsia: diffusion-weighted imaging and apparent diffusion coefficient-mapping as prognostic tools. Eur J Neurol 2006;13(3):309-10.
Schaefer PW, Buonanno FS, Gonzalez RG, Schwamm LH. Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia. Stroke 1997;28:1082-5.
Bartynski WS, Zeigler ZR, Shadduck RK, Lister J. Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation. Neurocrit Care 2005;3(1):33-45.
Noè A, Cappelli B, Biffi A, Chiesa R, et al. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome. Ital J Pediatr 2010;36:14.
Erer B, Polchi P, Lucarelli G, et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Bone Mar-row Transplant 1996;18(1):157-62.
Patel A, Ayto R, MacDonald DH. Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma. Br J Haematol 2013;161(5):607.
Pea F, Baccarani U, Tavio M, et al. Pharmacokinetic interaction between everolimus and anti-fungal triazoles in a liver transplant patient. Ann Pharmacother 2008;42(11):1711-6.
Greenberg ML, Fisher PG, Freeman C, et al. Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatr Blood Cancer 2005;45(5):644-8.
Minn AY, Fisher PG, Barnes PD, Dahl GV. A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation. Pediatr Blood Cancer 2007;48(2):213-7.